清鼻方治疗鼻咽癌的实验研究
|
摘要
鼻咽癌是我国常见的恶性肿瘤之一,在头颈部肿瘤中占首位,发病率有明显的地区分布。我国及东南亚地区较多见,其中广东中西部发病率最高。近年来NPC发病率逐年攀升,因其具体发病机制尚不明确,联合化疗近期效果显著,但毒副反应严重,容易导致不同程度的后遗症,严重影响患者的生活质量及预后。近年来中医药治疗鼻咽癌的优势备受国内外关注,已有实验和临床资料表明,中医药在提高肿瘤病人生活质量,延长生存时间,降低肿瘤复发和转移等方面具有独特的优势。
“清鼻方”是陈锐深教授临床治疗鼻咽癌的临床经验方,广泛用于晚期鼻咽癌的治疗及鼻咽癌放疗的辅助治疗,在临床使用多年,具有良好的临床疗效。
本课题将探讨“清鼻方”对免疫力低下小鼠非特异性免疫功能的影响及通过体外实验探讨“清鼻方”对CNE细胞增殖的影响,旨在从不同层面、不同靶点探讨“清鼻方”对鼻咽癌的作用机理,为临床使用提供科学的依据。
目的：
在建立免疫力低下模型小鼠基础上,应用清鼻方干预模型小鼠,研究清鼻方在增强机体免疫力的作用机理；在己分离出的鼻咽癌细胞株(CNE细胞)及血清药理学的基础上,通过细胞生物学、分子生物学技术,探讨清鼻方对CNE细胞的抑制作用。
方法：
(1)清鼻方对环磷酰胺诱导所致免疫力低下小鼠非特异性免疫功能的影响取健康雌雄各半的BALB/c种小白鼠70只,按随机区组法分为5组：模型对照组、清鼻方高剂量组、清鼻方低剂量组、干扰素阳性药对照药组及正常对照组。除正常对照组外,其余各组皮下注射环磷酰胺,按80mg/kg体重给药,连续给药3d造模。正常对照组、模型对照组、清鼻方高剂量组、清鼻方低剂量组均采取每天灌胃给药,干扰素组则采用隔天肌注给药,试验周期均为30天。以小鼠体重、脾脏称重、脾脏悬液细胞计数、血清IgA、IgG、IgM含量、T细胞亚群CD3/4/8表达水平进行评价。(2)清鼻方治疗效应对大鼠鼻咽上皮细胞增殖的影响研究制备中药复方清鼻方浓缩煎液。取健康雌雄各半SD大鼠12只,随机分为模型组6只和实验组6只。模型组采用生理盐水灌胃,而实验组采用中药清鼻方浓缩煎液灌胃,处理时长为5天。在大鼠腹主动脉取血,离心取上清制成含药血清直接作用于CNE细胞,并采用MTT法、流式细胞术,电子显微镜观察细胞生长曲线来研究清鼻方分别作用于CNE细胞后对肿瘤细胞生长的抑制情况,以及清鼻方诱导肿瘤细胞发生凋亡的情况。
结果：
(1)与空白组比较,各组小鼠体重、脾质量、脾脏指数、脾细胞总数均明显下降(P<0.01),其中模型组各数值均最低。骨髓有核细胞数各组与空白组比较,差异无统计学意义(P>0.05)。模型组IgA水平明显降低,干扰素组、低剂量组和高剂量组IgA水平明显升高(P<0.01); IgG水平方面,模型组、干扰素组均明显降低(P<0.01),清鼻方低剂量组和高剂量组变化均不明显(P>0.05)；模型组、干扰素组、低剂量组IgM水平均升高,高剂量组反而降低,但均无统计学差异(P<0.05)。(2)与模型组比较,各用药组骨髓有核细胞数变化不明显(P>0.05)。低剂量组在体重、脾质量、脾脏指数、脾细胞总数方面与之比较,两者均无统计学意义(P>0.05)；高剂量组在小鼠体重、脾质量、脾脏指数方面明显高于模型组(P<0.01)；干扰素组体重、脾质量方面与模型组对比,差异均明显具有统计学意义(P<0.01)。干扰素组、低剂量组和高剂量组IgA水平均明显升高(P<0.01)；干扰素组IgG变化不明显,清鼻方低剂量组和高剂量组IgG水平俊明显升高(P<0.05)；干扰素组和低剂量组均无统计学差异(P<0.05),高剂量组明显低于模型组,两者相比差异有统计学意义(P<0.05)。(3)小鼠外周血CD3、CD4、CD8的整体表达水平相对脾脏较低。小鼠造模后外周血CD3、 CD4、CD8表达水平无明显下降,而脾脏CD3、CD4、CD8表达水平则明显下降；给予干扰素和清鼻方低高剂量后CD3、CD4、CD8表达水平均有一定程度的提升,其中干扰素组接近正常组水平,清鼻方低、高剂量组则均未达到正常组水平。(4)MTT法比色结果显示,在作用24h后,不同浓度清鼻方含药血清对CNE细胞的抑制作用不明显。作用48h后,血清浓度5%、10%、15%对CNE细胞的抑制作用明显；作用72h后,血清浓度5%、10%、对CNE细胞的抑制作用明显。(5)CNE细胞的增殖曲线结果显示：未灭活的正常大鼠血清或含药血清(10%和15%)均具有具有抑制细胞增殖的效果。其中15%未灭活含药血清较10%未灭活含药血清具有更强的抑制CNE细胞增殖的作用。灭活的正常大鼠血清或含药血清(10%和15%)也出现类似的情况,但整体效应低于未灭活血清组。(6)细胞凋亡率方面,用10%含药血清和正常大鼠血清处理CNE细胞后,正常大鼠血清出现凋亡细胞(23%),含药血清出现更高的凋亡率31.0%；用15%含药血清和正常大鼠血清处理CNE细胞后,正常大鼠血清也出现凋亡细胞(25.3%),而15%含药血清凋亡率达33.9%。
结论：
清鼻方能减轻化疗药物所致的免疫抑制状态,调节机体的细胞免疫与体液免疫,使紊乱免疫机能趋于正常,这将于鼻咽癌患者恢复；清鼻方含药血清能抑制CNE细胞的增殖,诱导细胞凋亡,这可能是其重要作用机理。
Nasopharyngeal carcinoma (NPC for short), one of the common malignant tumors in China, is ranked as top above all head and neck cancer, with a significant regional distribution of incidence rate. It is more common in China and Southeast Asia, and among all, Guangdong is the highest. In recent years, NPC incidence rate has increased steadily, because its' specific pathogenesis is not certain. Although recent combination chemotherapy showed significant effect, but its'serious toxicity of side effect, easily lead to sequelae of different degree, severely affecting the quality of life and prognosis of the patients. Chinese medicine, as an effective adjuvant therapy, not only could alleviate radiation therapy side effects, enhance immunity, improve the tolerance of chemotherapy and radiation therapy, but also could improve patients' quality of life. Thus it has been increasingly used in clinical, and has become an important research topic in medical field. At the moment, Chinese medicine research has been more in-depth in China and overseas, and the researchers found that single herbs or Chinese herbal formula is indeed therapeutic, especially in immune regulation and tumor suppressor. Domestic Chinese Medicine treatment of NPC normally according to the treatment with syndrome differentiation and prescription studies, its exact mechanism of action remains to be elucidated."Nasal Cleaning Formula"(NCF for short), is formulated by Professor Chen Ruishen based on the "Qi" deficiency and contamination, as well as years of clinical practice experience, and has performed excellent clinical efficacy. Current research of NPC pathogenesis in immunology has progressed rapidly; the treatment of diseases in Chinese medicine is applying multi-target synergy. The author has studied the clinical efficacy and its mechanism of action of "Nasal Cleaning Formula" in the treatment of nasopharyngeal carcinoma.
1、Clinical Research Objective:To observe the clinical efficacy of the adjunctive therapy of "Nasal Cleaning Formula" in radiation therapy of nasopharyngeal cancer. Method:76cases of NPC patients were randomly divided into treatment group ("Nasal Cleaning Formula"+radiation therapy) and the control group (radiation therapy),38cases respectively. Control group using conventional radiation therapy, while treatment group using additional "Nasal Cleaning Formula", with a dose every day, a total of seven weeks. Skin mucosal damage and adverse events before and after treatment is observed. T cell subsets, IL-2, TNF-alpha and etc. before and after treatment are determined. Result:(1)No explicit difference (P<0.05) in term of age, gender, radiation dose, pathological staging, radiation treatment and other general information between two groups.(2) Oropharyngeal injury appeared mainly in1,2degrees among patients of treatment group after three weeks of radiation therapy, incidence rate of grade Ⅲ reaction was44.7%,57.9%in the control group; incidence of grade Ⅳ reaction in treatment group was0,15.8%in the control group, the difference is significant(P<0.05);after7weeks of radiation therapy, incidence of grade Ⅲ reaction in treatment group was52.63%,71.05%in the control group; incidence of grade IV reaction in treatment group was2.6%,31.57%in the control group, the difference is significant(P<0.01).(3)Reaction time for radioactive oropharyngeal to be appeared in the treatment group (14.3±1.76) d lower than the control group (19.3±1.56) d (P <0.01).(4) IL-2与TNF-α of treatment group after treatment higher than control group(P<0.01); CD3、CD4&CD4/CD8of treatment group significantly higher than control group.(5) The toxicity in skin, mucous membranes, gastrointestinal and bone marrow of the treatment group is lighter than the control group.Conclusion:"Nasal Cleaning Formula" has the effect of supplementing vital energy and nourishing yin, clearing away heat, detoxication and resolving blood stasis. It could alleviate and delay the injury of skin and mucus due to radiation therapy, and could also reduce the gastrointestinal, bone marrow suppression and other adverse reactions. Besides, it could mitigate the injury of immunity made by radiation therapy and regulate the immune function, leading to a better protection effect against injury after radiation therapy. Therefore, it could increase patients'quality of life by increasing the effect and reducing the toxins.
2、Laboratory Research Objectives:On the basis of the establishment of the rat model with low immunity, applying "Nasal Cleaning Formula" in interventions of rat model, to study the mechanism of "Nasal Cleaning Formula" in enhancing immunity of organism. Based on cell line (CNE cells) isolated from the nasopharyngeal carcinoma in China and serum pharmacology, explore the anticancer effect of "Nasal Cleaning Formula" against CNE cells through cell biology, molecular biology techniques. Method:(1)The effect of "Nasal Cleaning Formula"(NCF for short) on non-specific immune functions of immunosuppressive rats induced by cyclophosphamide70healthy BALB/c rats (both male&female50%) were randomly divided into5groups:model control group,"NCF" High Dosage Group,"NCF" Low Dosage Group, interferon positive control medicine group, normal control(blank) group. Every group except normal control group is given subcutaneous injection of cyclophosphamide, with multiple-doses of80mg/kg according to weight. Model control group,"NCF" High Dosage Group,"NCF" Low Dosage Group and normal control group were given medicine by intragastric administration, while interferon group were given medicine by intramuscular administration every other day, all with the testing cycle of30days. Evaluate by the body weight of rat, spleen weight, spleen suspension cell count, IgA, IgG and IgM level of serum and T-cell subsets CD3/4/8expression levels.(2)"NCF" treatment effects on the proliferation of nasopharyngeal epithelial cells in rats Preparation of Chinese herbal formula "NCF" concentrated decoction12healthy SD rats (both male&female50%) were randomly divided into6model groups and6experimental groups. Model groups were given normal saline through intragastric administration, while experimental groups were given "NCF" concentrated decoction through intragastric administration, with the testing cycle of5days. Blood was collected from rat's abdominal aorta, supernatant was made through centrifugation to make up medicine-contained serum to be act upon CNE cells, and by using MTT method, flow cytometry, electron microscope for growth curve observation, we can study the inhibition of the growth of tumor cells when "NCF" act on CNE cells, and also tumor cells apoptosis induced by "NCF". Results:(1)Compared to blank group, each group has the body weight of rats, spleen weight, spleen index, spleen cell count significantly decreased (P<0.01), while model control group hits the lowest for all values. When comparing the quantity of bone marrow cells (BMC) of each group with the blank group, there is no statistical significance (P>0.05). IgA level for model control group decreased significantly, but IgA level of interferon group,"NCF" Low Dosage Group and "NCF" High Dosage Group increased significantly (P<0.01). For IgG level, model control group and interferon group showed significant decrease (P<0.01), but "NCF" High Dosage Group and "NCF" Low Dosage Group showed insignificant change (P>0.05). Although IgM level of model control group, interferon group and "NCF" Low Dosage Group increased, level of "NCF" High Dosage Group decreased, but none of them showed statistical discrepancy(P<0.05).(2) Compared to model control group, the quantity of bone marrow cells (BMC) of each group with medication changed insignificantly (P>0.05). If we compared the body weight, spleen weight, spleen index, spleen cells count between "NCF" Low Dosage Group and model control group, both showed no statistical significance (P>0.05); Whereas the body weight, spleen weight, spleen index of "NCF" High Dosage Group significantly higher than model control group (P<0.01); The difference of the body weight, spleen weight between interferon group and model control group both showed obvious statistical significance(P<0.01). IgA level of interferon group,"NCF" Low Dosage Group and "NCF" High Dosage Group have increased significantly (P<0.01); IgG level of interferon group changed insignificantly, while IgG level of "NCF" Low Dosage Group and "NCF" High Dosage Group showed significant increase(P<0.05); There is no statistical discrepancy (P<0.05) between interferon group and "NCF" Low Dosage Group, while "NCF" High Dosage Group significantly lower than model control group, difference between them are statistical significant (P<0.05).(3)The overall expression levels of rat peripheral blood CD3, CD4, CD8are relatively lower than spleen, and showed no significant drop after modeling, but expression levels of spleen CD3, CD4, CD8decreased significantly. After giving interferon, high and low dosage of "NCF", CD3, CD4, CD8levels indicated certain degrees of increment. Among this, interferon group nearly reached the level of normal control group, while both "NCF" Low and High Dosage Group did not achieve.(4) Color comparison result of MTT method showed, after acting on for24hours, the inhibition of "NCF" medicine-contained serum of different concentration towards CNE cells was not significant. But after48hours, the inhibition effect of serum of5%,10%and15%concentration upon CNE cells was significant. After72hours, inhibition effect of serum of5%,10%concentration upon CNE cells was significant.(5) The growth curve of CNE cells showed:Activated serums of normal rat or medicine-contained (10%and15%) both possess cells growth inhibition effect. Activated medicine-contained serum of15%concentration are stronger than activated medicine-contained serum of10%in inhibiting CNE cells growth. Inactivated serums of normal rat or medicine-contained (10%and15%) also showed similar effect, but overall performance was lower than activated serum group.(6) For cells apoptosis rate, after using serum of normal rat and of medicine-contained (10%) to process CNE cells, there is apoptotic cells (23%) in serum of normal rat, whereas the apoptosis rate in medicine-contained serum is much higher (31.0%). By processing CNE cells using15%concentrated serum of normal rat and medicine-contained, apoptotic cells appeared in the normal rat serum (25.3%), while medicine-contained serum reached a total of33.9%apoptosis rate. Conclusion:"Nasal Cleaning Formula" could alleviate the immunosuppression caused by chemotherapy, regulate the cellular immunity and humoral immunity of organism, so as to reverse the immunity disorder, and promotes NPC patients recovery;"NCF" medicine-contained serum could inhibit the growth of CNE cells, inducing cells apoptosis, and this could possibly be its important mechanism.
“清鼻方”是陈锐深教授临床治疗鼻咽癌的临床经验方,广泛用于晚期鼻咽癌的治疗及鼻咽癌放疗的辅助治疗,在临床使用多年,具有良好的临床疗效。
本课题将探讨“清鼻方”对免疫力低下小鼠非特异性免疫功能的影响及通过体外实验探讨“清鼻方”对CNE细胞增殖的影响,旨在从不同层面、不同靶点探讨“清鼻方”对鼻咽癌的作用机理,为临床使用提供科学的依据。
目的：
在建立免疫力低下模型小鼠基础上,应用清鼻方干预模型小鼠,研究清鼻方在增强机体免疫力的作用机理；在己分离出的鼻咽癌细胞株(CNE细胞)及血清药理学的基础上,通过细胞生物学、分子生物学技术,探讨清鼻方对CNE细胞的抑制作用。
方法：
(1)清鼻方对环磷酰胺诱导所致免疫力低下小鼠非特异性免疫功能的影响取健康雌雄各半的BALB/c种小白鼠70只,按随机区组法分为5组：模型对照组、清鼻方高剂量组、清鼻方低剂量组、干扰素阳性药对照药组及正常对照组。除正常对照组外,其余各组皮下注射环磷酰胺,按80mg/kg体重给药,连续给药3d造模。正常对照组、模型对照组、清鼻方高剂量组、清鼻方低剂量组均采取每天灌胃给药,干扰素组则采用隔天肌注给药,试验周期均为30天。以小鼠体重、脾脏称重、脾脏悬液细胞计数、血清IgA、IgG、IgM含量、T细胞亚群CD3/4/8表达水平进行评价。(2)清鼻方治疗效应对大鼠鼻咽上皮细胞增殖的影响研究制备中药复方清鼻方浓缩煎液。取健康雌雄各半SD大鼠12只,随机分为模型组6只和实验组6只。模型组采用生理盐水灌胃,而实验组采用中药清鼻方浓缩煎液灌胃,处理时长为5天。在大鼠腹主动脉取血,离心取上清制成含药血清直接作用于CNE细胞,并采用MTT法、流式细胞术,电子显微镜观察细胞生长曲线来研究清鼻方分别作用于CNE细胞后对肿瘤细胞生长的抑制情况,以及清鼻方诱导肿瘤细胞发生凋亡的情况。
结果：
(1)与空白组比较,各组小鼠体重、脾质量、脾脏指数、脾细胞总数均明显下降(P<0.01),其中模型组各数值均最低。骨髓有核细胞数各组与空白组比较,差异无统计学意义(P>0.05)。模型组IgA水平明显降低,干扰素组、低剂量组和高剂量组IgA水平明显升高(P<0.01); IgG水平方面,模型组、干扰素组均明显降低(P<0.01),清鼻方低剂量组和高剂量组变化均不明显(P>0.05)；模型组、干扰素组、低剂量组IgM水平均升高,高剂量组反而降低,但均无统计学差异(P<0.05)。(2)与模型组比较,各用药组骨髓有核细胞数变化不明显(P>0.05)。低剂量组在体重、脾质量、脾脏指数、脾细胞总数方面与之比较,两者均无统计学意义(P>0.05)；高剂量组在小鼠体重、脾质量、脾脏指数方面明显高于模型组(P<0.01)；干扰素组体重、脾质量方面与模型组对比,差异均明显具有统计学意义(P<0.01)。干扰素组、低剂量组和高剂量组IgA水平均明显升高(P<0.01)；干扰素组IgG变化不明显,清鼻方低剂量组和高剂量组IgG水平俊明显升高(P<0.05)；干扰素组和低剂量组均无统计学差异(P<0.05),高剂量组明显低于模型组,两者相比差异有统计学意义(P<0.05)。(3)小鼠外周血CD3、CD4、CD8的整体表达水平相对脾脏较低。小鼠造模后外周血CD3、 CD4、CD8表达水平无明显下降,而脾脏CD3、CD4、CD8表达水平则明显下降；给予干扰素和清鼻方低高剂量后CD3、CD4、CD8表达水平均有一定程度的提升,其中干扰素组接近正常组水平,清鼻方低、高剂量组则均未达到正常组水平。(4)MTT法比色结果显示,在作用24h后,不同浓度清鼻方含药血清对CNE细胞的抑制作用不明显。作用48h后,血清浓度5%、10%、15%对CNE细胞的抑制作用明显；作用72h后,血清浓度5%、10%、对CNE细胞的抑制作用明显。(5)CNE细胞的增殖曲线结果显示：未灭活的正常大鼠血清或含药血清(10%和15%)均具有具有抑制细胞增殖的效果。其中15%未灭活含药血清较10%未灭活含药血清具有更强的抑制CNE细胞增殖的作用。灭活的正常大鼠血清或含药血清(10%和15%)也出现类似的情况,但整体效应低于未灭活血清组。(6)细胞凋亡率方面,用10%含药血清和正常大鼠血清处理CNE细胞后,正常大鼠血清出现凋亡细胞(23%),含药血清出现更高的凋亡率31.0%；用15%含药血清和正常大鼠血清处理CNE细胞后,正常大鼠血清也出现凋亡细胞(25.3%),而15%含药血清凋亡率达33.9%。
结论：
清鼻方能减轻化疗药物所致的免疫抑制状态,调节机体的细胞免疫与体液免疫,使紊乱免疫机能趋于正常,这将于鼻咽癌患者恢复；清鼻方含药血清能抑制CNE细胞的增殖,诱导细胞凋亡,这可能是其重要作用机理。
Nasopharyngeal carcinoma (NPC for short), one of the common malignant tumors in China, is ranked as top above all head and neck cancer, with a significant regional distribution of incidence rate. It is more common in China and Southeast Asia, and among all, Guangdong is the highest. In recent years, NPC incidence rate has increased steadily, because its' specific pathogenesis is not certain. Although recent combination chemotherapy showed significant effect, but its'serious toxicity of side effect, easily lead to sequelae of different degree, severely affecting the quality of life and prognosis of the patients. Chinese medicine, as an effective adjuvant therapy, not only could alleviate radiation therapy side effects, enhance immunity, improve the tolerance of chemotherapy and radiation therapy, but also could improve patients' quality of life. Thus it has been increasingly used in clinical, and has become an important research topic in medical field. At the moment, Chinese medicine research has been more in-depth in China and overseas, and the researchers found that single herbs or Chinese herbal formula is indeed therapeutic, especially in immune regulation and tumor suppressor. Domestic Chinese Medicine treatment of NPC normally according to the treatment with syndrome differentiation and prescription studies, its exact mechanism of action remains to be elucidated."Nasal Cleaning Formula"(NCF for short), is formulated by Professor Chen Ruishen based on the "Qi" deficiency and contamination, as well as years of clinical practice experience, and has performed excellent clinical efficacy. Current research of NPC pathogenesis in immunology has progressed rapidly; the treatment of diseases in Chinese medicine is applying multi-target synergy. The author has studied the clinical efficacy and its mechanism of action of "Nasal Cleaning Formula" in the treatment of nasopharyngeal carcinoma.
1、Clinical Research Objective:To observe the clinical efficacy of the adjunctive therapy of "Nasal Cleaning Formula" in radiation therapy of nasopharyngeal cancer. Method:76cases of NPC patients were randomly divided into treatment group ("Nasal Cleaning Formula"+radiation therapy) and the control group (radiation therapy),38cases respectively. Control group using conventional radiation therapy, while treatment group using additional "Nasal Cleaning Formula", with a dose every day, a total of seven weeks. Skin mucosal damage and adverse events before and after treatment is observed. T cell subsets, IL-2, TNF-alpha and etc. before and after treatment are determined. Result:(1)No explicit difference (P<0.05) in term of age, gender, radiation dose, pathological staging, radiation treatment and other general information between two groups.(2) Oropharyngeal injury appeared mainly in1,2degrees among patients of treatment group after three weeks of radiation therapy, incidence rate of grade Ⅲ reaction was44.7%,57.9%in the control group; incidence of grade Ⅳ reaction in treatment group was0,15.8%in the control group, the difference is significant(P<0.05);after7weeks of radiation therapy, incidence of grade Ⅲ reaction in treatment group was52.63%,71.05%in the control group; incidence of grade IV reaction in treatment group was2.6%,31.57%in the control group, the difference is significant(P<0.01).(3)Reaction time for radioactive oropharyngeal to be appeared in the treatment group (14.3±1.76) d lower than the control group (19.3±1.56) d (P <0.01).(4) IL-2与TNF-α of treatment group after treatment higher than control group(P<0.01); CD3、CD4&CD4/CD8of treatment group significantly higher than control group.(5) The toxicity in skin, mucous membranes, gastrointestinal and bone marrow of the treatment group is lighter than the control group.Conclusion:"Nasal Cleaning Formula" has the effect of supplementing vital energy and nourishing yin, clearing away heat, detoxication and resolving blood stasis. It could alleviate and delay the injury of skin and mucus due to radiation therapy, and could also reduce the gastrointestinal, bone marrow suppression and other adverse reactions. Besides, it could mitigate the injury of immunity made by radiation therapy and regulate the immune function, leading to a better protection effect against injury after radiation therapy. Therefore, it could increase patients'quality of life by increasing the effect and reducing the toxins.
2、Laboratory Research Objectives:On the basis of the establishment of the rat model with low immunity, applying "Nasal Cleaning Formula" in interventions of rat model, to study the mechanism of "Nasal Cleaning Formula" in enhancing immunity of organism. Based on cell line (CNE cells) isolated from the nasopharyngeal carcinoma in China and serum pharmacology, explore the anticancer effect of "Nasal Cleaning Formula" against CNE cells through cell biology, molecular biology techniques. Method:(1)The effect of "Nasal Cleaning Formula"(NCF for short) on non-specific immune functions of immunosuppressive rats induced by cyclophosphamide70healthy BALB/c rats (both male&female50%) were randomly divided into5groups:model control group,"NCF" High Dosage Group,"NCF" Low Dosage Group, interferon positive control medicine group, normal control(blank) group. Every group except normal control group is given subcutaneous injection of cyclophosphamide, with multiple-doses of80mg/kg according to weight. Model control group,"NCF" High Dosage Group,"NCF" Low Dosage Group and normal control group were given medicine by intragastric administration, while interferon group were given medicine by intramuscular administration every other day, all with the testing cycle of30days. Evaluate by the body weight of rat, spleen weight, spleen suspension cell count, IgA, IgG and IgM level of serum and T-cell subsets CD3/4/8expression levels.(2)"NCF" treatment effects on the proliferation of nasopharyngeal epithelial cells in rats Preparation of Chinese herbal formula "NCF" concentrated decoction12healthy SD rats (both male&female50%) were randomly divided into6model groups and6experimental groups. Model groups were given normal saline through intragastric administration, while experimental groups were given "NCF" concentrated decoction through intragastric administration, with the testing cycle of5days. Blood was collected from rat's abdominal aorta, supernatant was made through centrifugation to make up medicine-contained serum to be act upon CNE cells, and by using MTT method, flow cytometry, electron microscope for growth curve observation, we can study the inhibition of the growth of tumor cells when "NCF" act on CNE cells, and also tumor cells apoptosis induced by "NCF". Results:(1)Compared to blank group, each group has the body weight of rats, spleen weight, spleen index, spleen cell count significantly decreased (P<0.01), while model control group hits the lowest for all values. When comparing the quantity of bone marrow cells (BMC) of each group with the blank group, there is no statistical significance (P>0.05). IgA level for model control group decreased significantly, but IgA level of interferon group,"NCF" Low Dosage Group and "NCF" High Dosage Group increased significantly (P<0.01). For IgG level, model control group and interferon group showed significant decrease (P<0.01), but "NCF" High Dosage Group and "NCF" Low Dosage Group showed insignificant change (P>0.05). Although IgM level of model control group, interferon group and "NCF" Low Dosage Group increased, level of "NCF" High Dosage Group decreased, but none of them showed statistical discrepancy(P<0.05).(2) Compared to model control group, the quantity of bone marrow cells (BMC) of each group with medication changed insignificantly (P>0.05). If we compared the body weight, spleen weight, spleen index, spleen cells count between "NCF" Low Dosage Group and model control group, both showed no statistical significance (P>0.05); Whereas the body weight, spleen weight, spleen index of "NCF" High Dosage Group significantly higher than model control group (P<0.01); The difference of the body weight, spleen weight between interferon group and model control group both showed obvious statistical significance(P<0.01). IgA level of interferon group,"NCF" Low Dosage Group and "NCF" High Dosage Group have increased significantly (P<0.01); IgG level of interferon group changed insignificantly, while IgG level of "NCF" Low Dosage Group and "NCF" High Dosage Group showed significant increase(P<0.05); There is no statistical discrepancy (P<0.05) between interferon group and "NCF" Low Dosage Group, while "NCF" High Dosage Group significantly lower than model control group, difference between them are statistical significant (P<0.05).(3)The overall expression levels of rat peripheral blood CD3, CD4, CD8are relatively lower than spleen, and showed no significant drop after modeling, but expression levels of spleen CD3, CD4, CD8decreased significantly. After giving interferon, high and low dosage of "NCF", CD3, CD4, CD8levels indicated certain degrees of increment. Among this, interferon group nearly reached the level of normal control group, while both "NCF" Low and High Dosage Group did not achieve.(4) Color comparison result of MTT method showed, after acting on for24hours, the inhibition of "NCF" medicine-contained serum of different concentration towards CNE cells was not significant. But after48hours, the inhibition effect of serum of5%,10%and15%concentration upon CNE cells was significant. After72hours, inhibition effect of serum of5%,10%concentration upon CNE cells was significant.(5) The growth curve of CNE cells showed:Activated serums of normal rat or medicine-contained (10%and15%) both possess cells growth inhibition effect. Activated medicine-contained serum of15%concentration are stronger than activated medicine-contained serum of10%in inhibiting CNE cells growth. Inactivated serums of normal rat or medicine-contained (10%and15%) also showed similar effect, but overall performance was lower than activated serum group.(6) For cells apoptosis rate, after using serum of normal rat and of medicine-contained (10%) to process CNE cells, there is apoptotic cells (23%) in serum of normal rat, whereas the apoptosis rate in medicine-contained serum is much higher (31.0%). By processing CNE cells using15%concentrated serum of normal rat and medicine-contained, apoptotic cells appeared in the normal rat serum (25.3%), while medicine-contained serum reached a total of33.9%apoptosis rate. Conclusion:"Nasal Cleaning Formula" could alleviate the immunosuppression caused by chemotherapy, regulate the cellular immunity and humoral immunity of organism, so as to reverse the immunity disorder, and promotes NPC patients recovery;"NCF" medicine-contained serum could inhibit the growth of CNE cells, inducing cells apoptosis, and this could possibly be its important mechanism.
引文
[1]柯霞,洪苏玲.526例鼻咽癌患者临床资料分析[J].重庆医学,2010,39(3)：278-279.
[2]谷铣之,殷蔚伯.肿瘤放射治疗学[M].第3版.北京：北京医科大学、中国协和医科大学联合出版社,2002：537.
[3]林力,文浩,杨加林,等,单纯根治性放疗与放疗联合化疗治疗鼻咽癌的远期疗效分析[J].中国肿瘤临床与康复,2000,7(4)：49.
[4]马骏,麦海强,莫浩元,等.鼻咽癌放射治疗失败原因分析[J].癌症,2000,19(11)：1016.
[5]韩旻雁,银恭举,陈维清.中国人群鼻咽癌发病危险因素的Meta分析[J].中国热带医学.2005,5(7)：1442-1442.
[6]刘奕龙,曹卡加,马国胜,等.广州市鼻咽癌发病率和死亡率分析[J].中国肿瘤.2008,(7)：563-564.
[7]Parkin DM, Whelan S, Ferlay J, Storm H, eds. Cancer Incidence in Five Continents. [J]. Cancer Base No.7. Lyon:IARC Press;2005.
[8]Buell P. The effect of migration on the risk of nasopharyngeal cancer among Chinese[J]. Cancer Res.1974;34:1189-1191.
[9]田勇泉.耳鼻咽喉-头颈外科学[M].北京：人民卫生出版社,2004：170.
[10]Talbot S J, Craw ford DH. Viruses and cancer[J]. Medicine,2005,33(3):39-42.
[11]Old LT,Bogse AE, Dettgen HF,et al. Precipitating cultured Burk itt's lymphoma cell[J].Proc Nat 1 A cad Sci USA,1996,56(6):1699-1704.
[12]Fahraeus R,Fu HL, Emberg I,et al. Expression of Ep stein-Barrvirus-encoded proteins in nasopharyngeal carcinoma [J]. Int J Cancer,1988,42(3):329-338.
[13]Fielding CA, Sandvej K, MehlA, et al. Eb stein-Barr virusLMP-1 natural sequence variants differ in their potential to activate cellular signaling pathways[J]. Viral,2001,75(19):9129-9141.
[14]Chang ET, Adami HO. The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev.2006:15:1765-1777.
[15]黄选兆,汪吉宝,等.实用耳鼻喉头颈外科学[M].第2版.北京：人民卫生出版社,2008：431-437.
[16]汤钊猷.现代肿瘤学[M].第2版.上海：上海医科大学出版社,2000：277.
[17]陈灏珠.实用内科学[M].第11版.北京：人民卫生出版社,2002：94.
[18]徐从高,张茂宏,杨兴季,等译.癌肿瘤学原理和实践[M].第5版.济南：山东科学技术出版社,2000：66-70.
[19]龚非力.医学免疫学[M].北京：科学出版社,2006：105-109.
[20]胡挺,张顺,徐焕龙.鼻咽癌患者细胞免疫功能变化的观察[J].现代实用医学.2006,18(5)：321-322.
[21]付迎辉,阎嘉茵,杜晓光,等.乳癌患者血.清TNF、IL-2、IL-6检测[J].郑州大学学报(医学版),2002,37(2)：215-216.
[22]韩晓红,石远凯,冯奉仪,等.流式细胞仪分析肿瘤患者免疫功能变化[J].实用癌症杂志,1999,14(5)：273-275,188-189.
[23]Carmichael A, Wills M. The immunology of infection[J]. Medicine,2005,33(3):3-9.
[24]孙蕾,常雅萍.病毒逃逸免疫细胞杀伤机制[J].国外医学·免疫学分册,2002,25(5)：265-268.
[25]刘伟胜,徐凯.肿瘤科专病中医临床诊治,北京：人民卫生出版社,2000：1.
[26]李佩文.中西医临床肿瘤学.北京：中国医药出版社,1996：244.
[27]苏胜发,卢泰祥,赵充,等.调强放疗总疗程时间延长对局部晚期鼻咽癌疗效的影响[J].中华放射肿瘤学杂志,2010,19(3)：181-184.
[28]SHU-ZHEN LAI. Int. J. Radiation On cology Biol. Phys. published online 20 July 2010.
[29]肖巍魏,卢泰祥,赵充,等.调强放疗技术对鼻咽癌UICC/AJCC分期的影响[J].中华放射肿瘤杂志,2010,19(3)：185-189.
[30]苏胜发,卢泰祥.鼻咽癌治疗进展[J].肿瘤预防与治疗,2010,23(1)：66-70.
[31]赵充,肖巍魏,韩非,等.419例鼻咽癌患者调强放疗疗效和影响[J].中华放射肿瘤杂志,2010,19(3)：191-196.
[32]徐鹭英,潘建基,郑崴,等.安多霖胶囊配合放射治疗鼻咽癌增效作用研究[J].BMCcancer2010,10:39
[33]王仁生.128例初治鼻咽癌调强适形放疗临床分析[J].肿瘤防治研究,2010,37(5)：250.
[34]Pecaut MJ, Nelson GA, Gridley DS, et al. Dose and dose rate effects of whole body gamma-irradiation:I lymphocytes and lymphoid organ s[J]. In Vivo,2001,15(5):195-208.
[35]任亮,顾涛,徐洁洁.鼻咽癌患者放疗前后血清SE-cad、IL-2、SIL-2R和TNF-α检测的临床意义[J].放射免疫学杂志,2006,19(5)：373-374.
[36]朱小东,放射治疗对鼻咽癌患者细胞免疫功能的影响[J].河南肿瘤学杂志1997,10(6)：4541.
[37]吴维光,赵燕,张积仁,等.化疗对肝癌患者T淋巴细胞内IL-2、IFN-γ的影响[J].实用癌症杂志,2001,1(16)：176-179.
[38]李芳,朱怀仕,贾平,等.卵巢癌患者功能的影响术后NDV-ATV-ASI与化疗对免疫功能的影响[J].现代妇产科进展,2003,12(5)：339-341.
[39]屠规益.对《NCCN肿瘤学临床实践指南》中有关头颈肿瘤部分的一点看法[J].临床耳鼻咽喉头颈外科杂志.2010,24(4)：145-146.
[40]屠规益.对NCCN头颈部肿瘤临床指引的一些意见[J].循证医学.2010,10(1)：57-59.
[41]袁太泽,徐理华,木圣,等.西妥昔单抗联合电离辐射对鼻咽癌细胞的作用[J].肿瘤防治研究,2011,(4)：373-376.
[42]刘皈阳,张鑫宇,王伟兰,等.西妥昔单抗治疗中晚期恶性肿瘤的疗效和安全性评价[J].中国医院药学杂志,2011,31(2)：126-129.
[43]王华庆,侯芸.分子靶向药物贝伐单抗研究进展[J].中国肿瘤,2005,14(11)：716-719.
[44]王玉,方明治.贝伐单抗在部分实体肿瘤中临床应用的研究进展[J].肿瘤,2011,31(4)：379-385.
[45]蔡美玲,祝亚平,万小平,等.贝伐单抗在卵巢癌中的应用[J].现代妇产科进展,2008,17(8)：624-626.
[46]庄洪卿,赵路军,王军,等.贝伐单抗辐射增敏机制研究进展[J].中国肿瘤临床与康复,2011,18(5)：477-480.
[47]孙影,刘巍,杨方.光动力疗法联合贝伐珠单抗治疗裸鼠U87胶质瘤的实验研究[J].中国激光医学杂志,2011,20(3)：149-153,202-203.
[48]Ang KK, Berkey BA, Tu X, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma[J]. Cancer Res,2002,62(24):7350-7356.
[49]Chua DT, Nicholls JM, Sham JS, et al. Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy[J]. Int J Radiat Oncol Biol Phys,2004,59(1):11-20.
[50]Eriksen JG, Steriniche T, Askaa J, et al. The prognostic value of epidermal growth factor receptor is related to tumor differentiation and the over all treatment time of radio therapy in squamous cell carcinomas of the head and neck[J].Int J Radiat Oncol Biol Phys,2004,58(2):561-566.
[51]Bentzen SM, Atasoy BM, Daley FM, et al. Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as apredictive fact or for a benefit from accelerated radiation therapy in arandomized controlled trial[J].J Clin Oncol,2005,23(24):5437-5439.
[52]刘孟娟,周陈西,王增,等.83例西妥昔单抗联合放化疗不良反应分析[J].中国现代应用药学,2011,38(5)：485-488.
[53]王朴.生地黄的现代药理研究与临床应用[J].中国中医药现代远程教育.2008,6(8)：986.
[54]夏聪华,石森林,葛卫红,等.玄参药理活性研究进展[J].中国药师.2008,11(8)：911-912.
[55]张健萍,李连珍,赵洪江,等.牡丹皮的化学成分、药理作用及临床应用研究概况[J].中华中医药杂志.2006,21(5)：295-297.
[56]王林青.中药金银花提取物杭炎作用研究[J].中国畜牧兽医.2008,35(8)：82.
[57]戴幼艺,刘安保,戴新华.西乐葆对鼻咽癌CNE-1细胞增殖和凋亡的影响.中国现代医学杂志.20(7)：988-991.
[58]刘伟胜,徐凯,等.肿瘤科专病中医临床诊治[M].第2版,北京：人民卫生出版社,2005,1.
[59]田道法,何迎春.鼻咽癌前病“气虚染毒”病机理论研究[J].中医耳鼻喉科学研究杂志.2008,7(1)：24-29.
[60]Cho W C, Chen H Y. Clinical efficacy of traditional Chinese medicine as a concomitant therapy for nasopharyngeal carcinoma:a systematic review and meta-analysis[J]. Cancer Invest,2009,27(3):334-344.
[61]曹远东,孙新臣,成红艳,等.汉防己甲素配合放射线增敏治疗鼻咽癌的临床研究[J].东南大学学报(医学版),2008,27(2)：106-109.
[62]谢强,赵荡,刘兴京,等.复方苦参注射液联合适形调强放疗治疗鼻咽癌的临床研究[J].国际内科学杂志,2008,35(3)：133-135.
[63]陈绪元,朱宇熹,陈晓品,等.平消胶囊与放疗同步治疗中晚期鼻咽癌增敏研究[J].临床肿瘤学杂志,2005,10(02)：163-165.
[64]苏旭春,肖柳珍,刘城林,等.普济煎液配合放、化疗治疗EB病毒感染鼻咽癌30例临床观 察[J].中医药导报,2005,(01)：32-33+36.
[65]金红,吴湘玮.养阴解毒法减低鼻咽癌放射反应24例疗效观察[J].山东中医杂志,2005,24(1)：17-19.
[66]童克家,王存吉.口疳清热汤治疗鼻咽癌放疗口咽黏膜毒副反应33例[J].中医药导报,2011,17(5)：30-32.
[67]刘淑美.生脉饮加味治疗鼻咽癌放疗时涎腺受损的临床研究[J].中国医药导报,2010,7(16)：13-15.
[68]王旺胜.养阴清热口服液对鼻咽癌放疗所致唾液腺损伤影响的临床研究[J].时珍国医国药,2008,19(3)：729-730.
[69]Bao Y X, Wong C K, Leung S F, et al. Clinical studies ofimmunomodulatory activities of Yunzhi-Danshen in patients with nasopharyngeal carcinoma[J]. J Altern Complement Med,2006,12(8):771-776.
[70]袁国荣,卢丽琴,钦志泉,等.加味清营汤对鼻咽癌放疗增效减毒的临床研究[J].中医药学刊,2006,24(4)：670-671.
[71]许利纯,张红,曾柏荣.血栓通加归七软坚散外敷治疗鼻咽癌放疗后张口困难疗效观察[J].中国中医药信息杂志,2007,14(1)：60-60.
[72]彭桂原.痰热清注射液治疗鼻咽癌放疗所致放射性咽喉炎临床观察[J].中国中医急症,2008,17(6)：761-762
[73]赖振源,任益民,黄碧松.中西医癌症诊断与治疗汇编[M].第1版,中华民国中医癌症医学会、中华民国中医肝病医学会、台湾中医皮肤科1学会联合出版.中华民国98年,152-153.
[74]Xu JH, et al. Curcumin inducing apoptosis and inhibiting expression of P210bcr/ abl protein in human chronic myelogenous leukemia k562 cells[J]. FAS EB Journal, 2000,14(8):1516.
[75]Lin JK, Lin-shiau SY. Mechanisms of cancer chemoprevention by curcumin [J]. Proc Nat 1 Sci Counc ROC(B),2002,25(2):59-66.
[76]麦镇江.姜黄素的药理作用研究进展[J].中药材,2004,27(9)：698-701.
[77]曾山,姚运红.姜黄素与化疗药物联合抗癌作用的研究进展[J].实用癌症,2010,25(2)：218-220.
[78]Zheng LD, Tong QS, Wu CH. Inhibitory effects of curcumin on apoptosis of human ovary cancer cell line A2780 and its molecular mechanism[J]. Ai Zheng,2002,21(12):1296-1300.
[79]许刚,黄文.姜黄素防治肿瘤的机制研究进展[J].国外医学生理病理科学与临床分册,2003,23(2)：152-154.
[80]赵承光,杨菊,梁栋楼,等.新型含氟姜黄素类似物的合成、晶体结构及抗肿瘤活性[J].有机化学,2010,30(2)：289-294.
[81]刘强和,孔中雨,向秋,等EGCG对鼻咽癌细胞株CNE-1生长及其survivin表达的影响[J].山东医药.2009,49(10)：26-27.
[82]湛达河,胡建兵,达世俭,等.雷公藤红素对鼻咽癌CNE-1细胞增殖抑制和放射增敏作用的初步研究[J].癌症进展.2010,8(5)：491-499.
[83]刘姬艳,马润娣,于立坚,土贝母苷甲对人鼻咽癌上皮细胞丝裂原活化蛋白激酶活性的影响[J].北京中医,2007,26(2)：119-121.
[84]翁昔阳,马润娣,于立坚.土贝母营甲诱导人鼻咽癌细胞CNE-2Z凋亡[J].癌症,2003,22(8)：806-811.
[85]孙伟,肖家祁,王淳凯,等.精油对人鼻咽癌细胞生长抑制的研究[J].上海中医药杂志,2005,39(9)：53-55.
[86]顾生玖,杨娜,朱开梅.槲皮素抑制人鼻咽癌CNE2细胞生长并诱导其凋亡的研究[J].中国实验方剂学杂志,2011,17(13)：192-194.
[87]韦世秀,刘成军,李牡艳,等.眼镜蛇毒神经生长因子诱导人鼻咽癌CNE-2细胞凋亡作用的研究[J].中国医院药学杂志,2008,28(22)：1909-1912.
[88]唐艳,曹建平,樊赛军,等.青蒿素对人鼻咽癌CNE细胞的放射增敏作用及机制的研究中华放射医学与防护杂志[J].2010,30(3)：280-282
[89]向银洲,余林,魏莲枝,等.冬凌草甲素对鼻咽癌HNE-1细胞株生长及其PCNA、Caspase-3表达的影响[J].山东医药,2010,50(50)：20-22.
[90]陈增边.黄芪多糖的抑瘤作用及注射用黄芪多糖对鼻咽癌放射治疗患者免疫功能的影响[J].临床医学.2010,30(5)：23-24.
[91]韦世秀,刘成军,李牡艳,等.黄芪注射液诱导人鼻咽癌CNE-2细胞凋亡及对细胞周期阻滞的研究[J].广西医科大学学报,2007,(05)：704-705.
[92]梅全喜,刘朝晖.中药复方防治鼻咽癌的药理研究进展[J].中国民族民间医药,2010,22-24.
[93]胡彬雅,田道法,何迎春.益气解毒颗粒影响鼻咽癌细胞HNE1增殖活力的实验研究[J].临床耳鼻喉头颈外科杂志.2009,23(12)：558-560.
[94]邓国英,范晓磊,杨如虹,等.参杞合剂对人鼻咽癌细胞CNE细胞周期及凋亡的影响[J].中国微生态学杂志,2007,19(3)：246-248.
[95]范晓磊,邓国英,周慧敏.参杞合剂诱导鼻咽癌细胞凋亡及其作用机制探讨[J].中医杂志.2008,49(5)：356-358.
[96]刘宗潮,简少文,冯公侃,等.鼻咽清毒剂对EB病毒抗原表达抑制作用和细胞毒作用的研究[J].中草药,1999,30(增刊)：158-159.
[97]韩虹,盛晓丽,崔勇,等.鼻咽清毒颗粒对鼻咽癌的体内抑制作用[J].广东医学,2009,30(9)：1244-1245.
[98]刘宗潮,简少文,李华忠,等.抗EB病毒口服液对EB病毒转化力的抑制作用.肿瘤防治杂志,2004,11(8)：790-792.
[99]刘宗潮,简少文,李华忠,等.抗EB病毒口服液对EB病毒抗原表达的抑制作用及其细胞毒作用.中草药.2004,35(5)：542-545.
[100]林壮民,王爱平,梅清华,等.抗EB病毒口服液对Beagle犬的长期毒性研究.中国药房,2006,17(14)：1054-1056.
[101]林壮民,贾冬,兰树敏,等.抗EB病毒口服液对大鼠的长期毒性实验.中药材,2006,29(6)：583-585.
[102]梅全喜,钟希文,符立梧,等.不同中药组方对人鼻咽癌细胞CNE-2体外抑制作用的比较研究.中国药房.2009.20(15)：1130-1131.
[103]景艳,唐安洲.中药在鼻咽癌综合治疗中的研究进展[J].实用医学杂 志.2010,26(9)：1487-1489.
[104]高月娟,孟妍,张艳丽.太子参抗应激作用的实验研究[J].齐齐哈尔医学院学报,2011,32(12)：1886-1887.
[105]王朴.生地黄的现代药理研究与临床应用[J].中国中医药现代远程教育.2008,6(8)：986.
[106]朱良春.朱良春用药经验集[M].第2版.长沙：湖南科学技术出版社.2007.10：226-227.
[107]李元青,马成杰,陈信义,等.三七活性成分抗肿瘤作用及其免疫学机制初探[J].北京中医药大学学报(中医临床版),2008,15(1)：17-19.
[108]Kastelan Z,Lukac E,Derezic D,et al.Lymphocyte subsets, lymphocyte reactivity to mitogens, NK cell activity and neutrophil and monocyte phagocytic functions in patients with bladder carcinoma [J].Anticancer Res,2003,23(6):5185.
[109]Tsai JP,Chen HW,Cheng ML,et al.Analysis of host versus tumor interaction in cancer patients:opposing role of transforming growth factor-β1 and interleukin-6 in the development of in situ tumor immunity[J].Immunobiology,2005,210(9):661-671.
[110]吕贺,朴成国,李香丹,等.中药抗肿瘤机制的研究现状[J].医学综述,2011,17(19)：3004-3006.
[111]Van Sandick J W,Boermeester M A,Gisbertz S S,et al.Lymphocyte subsets and T(h)1/T(h)2 immune responses in patients with ade2 nocarcinoma of the esophagus or oesophagogastric junction relation t opTNM stage and clinical outcome[J].Cancer Immunol Imnmnother,2003,52(10):617.
[112]Hadden J w.Immunodeficiency and cancer:prospects for correction [J].Int immunopharmacology,2003,3 (8):1061.
[113]何耀溅.大计量化疗治疗恶性肿瘤[J].匡际医药卫生报,2004,10(20)：56。
[114]王晓燕,徐爱运.化疗药物的毒副反应及护理[J].中华现代护理学杂志,2005,2(11)：1206-1207.
[115]欧阳素贞,王双山,田素香等.淫羊藿一蜂胶合剂促进鸡细胞免疫的研究[J].畜牧兽医学报,2006,37(1)：80-83.
[116]席孝贤,贺新怀.中药相关成分对T细胞亚群的调节作用[J].陕西中医学院学报,2002,25(2)：51-533.
[117]胡宇莉,廖晓兵,黎建华等.穿心莲对肉鸡体液免疫的影响[J].中国兽药杂志,2004,40(9)：24-27.
[118]吴小丽,蔡云清,赵岩等.蒲公英提取物对小鼠免疫功能的调节作用[J].南京医科大学学报(自然科学版),2005,25(3)：163-165.
[119]储岳峰,颜新敏,胡元亮等.几种中药成分的免疫增强活性及其作用效果[J].中国兽医科技,2005,35(1)：67-70.
[120]李虹,马莉,等.鼻咽癌患者外周血T细胞亚群及活化T淋巴细胞的检测及放疗后对其变化的影响[J].微量元素与健康研究,2006,23(3)：10-12
[121]王朝阳,李桂生,等.局部晚期鼻咽癌患者放化疗及随访过程中T细胞亚群的变化规律[J].实用医学杂志,2008,24(15)：2581-2583.
[122]方征,李鸣,等.鼻咽癌患者外周血NK细胞及T细胞亚群的变化[J].湖南医学,2001,18(6)：412-414.
[123]聂明,唐安洲,黄光武,等.鼻咽癌患者放疗前后外周血EBV-DNA和细胞免疫水平的研究[J].肿瘤防治研究,2011,38(04)：380-383.
[124]应妩,王毓三.全国临床检验操作规程[M].第二版,南京：南京东南大学出版社,1997； 361
[125]毛明华,黄世超,余慧珠.肿瘤患者放、化疗后外周血淋巴细胞损伤和免疫功能改变的研究[J].肿瘤,2004,24(6)：589-591.
[126]梅全喜.鼻咽癌的中医治疗.北京：中国中医药出版社,2010：176.
[127]刘成军,韦世秀,李牡艳,等.黄芪注射液对人鼻咽癌CNE-2细胞株的抑制作用研究[J].中国药房,2005,16(18)：1376-1378.
[128]阿依恒·曲库尔汗,尼力帕尔·阿力木,亚力坤·亚生,等Genistein对人鼻咽癌细胞系CNE抑制增殖和促进凋亡的作用及机制探讨[J].临床耳鼻咽喉头颈外科杂志,2011,25(18)：843-847.
[129]蔡于琛,冼励坚.小檗碱体内外对人鼻咽癌细胞CNE-2生长的抑制作用[J].中草药,2006,37(10)：1521-1526.
[130]罗晓婷,熊亮,李思思,等.橙皮苷提取物对人鼻咽癌CNE-2Z细胞增殖和细胞周期的影响[J].时珍国医国药,2011,22(9)：2202-2204.
[131]Dunne AL, Price ME, Mothersill C,et al.Relationship between clonogenic radiosensitivity, radiation-induced apoptosis and DNA damage/repair in human colon cancer cells [J].Br J Cancer,2003,89(12):2277-2283.
[132]Melet A, Song K, Bucur O,et al.Apoptotic pathways in tumor progression and therapy [J].Adv Exp Med Biol,2008,615:47-79.
[2]谷铣之,殷蔚伯.肿瘤放射治疗学[M].第3版.北京：北京医科大学、中国协和医科大学联合出版社,2002：537.
[3]林力,文浩,杨加林,等,单纯根治性放疗与放疗联合化疗治疗鼻咽癌的远期疗效分析[J].中国肿瘤临床与康复,2000,7(4)：49.
[4]马骏,麦海强,莫浩元,等.鼻咽癌放射治疗失败原因分析[J].癌症,2000,19(11)：1016.
[5]韩旻雁,银恭举,陈维清.中国人群鼻咽癌发病危险因素的Meta分析[J].中国热带医学.2005,5(7)：1442-1442.
[6]刘奕龙,曹卡加,马国胜,等.广州市鼻咽癌发病率和死亡率分析[J].中国肿瘤.2008,(7)：563-564.
[7]Parkin DM, Whelan S, Ferlay J, Storm H, eds. Cancer Incidence in Five Continents. [J]. Cancer Base No.7. Lyon:IARC Press;2005.
[8]Buell P. The effect of migration on the risk of nasopharyngeal cancer among Chinese[J]. Cancer Res.1974;34:1189-1191.
[9]田勇泉.耳鼻咽喉-头颈外科学[M].北京：人民卫生出版社,2004：170.
[10]Talbot S J, Craw ford DH. Viruses and cancer[J]. Medicine,2005,33(3):39-42.
[11]Old LT,Bogse AE, Dettgen HF,et al. Precipitating cultured Burk itt's lymphoma cell[J].Proc Nat 1 A cad Sci USA,1996,56(6):1699-1704.
[12]Fahraeus R,Fu HL, Emberg I,et al. Expression of Ep stein-Barrvirus-encoded proteins in nasopharyngeal carcinoma [J]. Int J Cancer,1988,42(3):329-338.
[13]Fielding CA, Sandvej K, MehlA, et al. Eb stein-Barr virusLMP-1 natural sequence variants differ in their potential to activate cellular signaling pathways[J]. Viral,2001,75(19):9129-9141.
[14]Chang ET, Adami HO. The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev.2006:15:1765-1777.
[15]黄选兆,汪吉宝,等.实用耳鼻喉头颈外科学[M].第2版.北京：人民卫生出版社,2008：431-437.
[16]汤钊猷.现代肿瘤学[M].第2版.上海：上海医科大学出版社,2000：277.
[17]陈灏珠.实用内科学[M].第11版.北京：人民卫生出版社,2002：94.
[18]徐从高,张茂宏,杨兴季,等译.癌肿瘤学原理和实践[M].第5版.济南：山东科学技术出版社,2000：66-70.
[19]龚非力.医学免疫学[M].北京：科学出版社,2006：105-109.
[20]胡挺,张顺,徐焕龙.鼻咽癌患者细胞免疫功能变化的观察[J].现代实用医学.2006,18(5)：321-322.
[21]付迎辉,阎嘉茵,杜晓光,等.乳癌患者血.清TNF、IL-2、IL-6检测[J].郑州大学学报(医学版),2002,37(2)：215-216.
[22]韩晓红,石远凯,冯奉仪,等.流式细胞仪分析肿瘤患者免疫功能变化[J].实用癌症杂志,1999,14(5)：273-275,188-189.
[23]Carmichael A, Wills M. The immunology of infection[J]. Medicine,2005,33(3):3-9.
[24]孙蕾,常雅萍.病毒逃逸免疫细胞杀伤机制[J].国外医学·免疫学分册,2002,25(5)：265-268.
[25]刘伟胜,徐凯.肿瘤科专病中医临床诊治,北京：人民卫生出版社,2000：1.
[26]李佩文.中西医临床肿瘤学.北京：中国医药出版社,1996：244.
[27]苏胜发,卢泰祥,赵充,等.调强放疗总疗程时间延长对局部晚期鼻咽癌疗效的影响[J].中华放射肿瘤学杂志,2010,19(3)：181-184.
[28]SHU-ZHEN LAI. Int. J. Radiation On cology Biol. Phys. published online 20 July 2010.
[29]肖巍魏,卢泰祥,赵充,等.调强放疗技术对鼻咽癌UICC/AJCC分期的影响[J].中华放射肿瘤杂志,2010,19(3)：185-189.
[30]苏胜发,卢泰祥.鼻咽癌治疗进展[J].肿瘤预防与治疗,2010,23(1)：66-70.
[31]赵充,肖巍魏,韩非,等.419例鼻咽癌患者调强放疗疗效和影响[J].中华放射肿瘤杂志,2010,19(3)：191-196.
[32]徐鹭英,潘建基,郑崴,等.安多霖胶囊配合放射治疗鼻咽癌增效作用研究[J].BMCcancer2010,10:39
[33]王仁生.128例初治鼻咽癌调强适形放疗临床分析[J].肿瘤防治研究,2010,37(5)：250.
[34]Pecaut MJ, Nelson GA, Gridley DS, et al. Dose and dose rate effects of whole body gamma-irradiation:I lymphocytes and lymphoid organ s[J]. In Vivo,2001,15(5):195-208.
[35]任亮,顾涛,徐洁洁.鼻咽癌患者放疗前后血清SE-cad、IL-2、SIL-2R和TNF-α检测的临床意义[J].放射免疫学杂志,2006,19(5)：373-374.
[36]朱小东,放射治疗对鼻咽癌患者细胞免疫功能的影响[J].河南肿瘤学杂志1997,10(6)：4541.
[37]吴维光,赵燕,张积仁,等.化疗对肝癌患者T淋巴细胞内IL-2、IFN-γ的影响[J].实用癌症杂志,2001,1(16)：176-179.
[38]李芳,朱怀仕,贾平,等.卵巢癌患者功能的影响术后NDV-ATV-ASI与化疗对免疫功能的影响[J].现代妇产科进展,2003,12(5)：339-341.
[39]屠规益.对《NCCN肿瘤学临床实践指南》中有关头颈肿瘤部分的一点看法[J].临床耳鼻咽喉头颈外科杂志.2010,24(4)：145-146.
[40]屠规益.对NCCN头颈部肿瘤临床指引的一些意见[J].循证医学.2010,10(1)：57-59.
[41]袁太泽,徐理华,木圣,等.西妥昔单抗联合电离辐射对鼻咽癌细胞的作用[J].肿瘤防治研究,2011,(4)：373-376.
[42]刘皈阳,张鑫宇,王伟兰,等.西妥昔单抗治疗中晚期恶性肿瘤的疗效和安全性评价[J].中国医院药学杂志,2011,31(2)：126-129.
[43]王华庆,侯芸.分子靶向药物贝伐单抗研究进展[J].中国肿瘤,2005,14(11)：716-719.
[44]王玉,方明治.贝伐单抗在部分实体肿瘤中临床应用的研究进展[J].肿瘤,2011,31(4)：379-385.
[45]蔡美玲,祝亚平,万小平,等.贝伐单抗在卵巢癌中的应用[J].现代妇产科进展,2008,17(8)：624-626.
[46]庄洪卿,赵路军,王军,等.贝伐单抗辐射增敏机制研究进展[J].中国肿瘤临床与康复,2011,18(5)：477-480.
[47]孙影,刘巍,杨方.光动力疗法联合贝伐珠单抗治疗裸鼠U87胶质瘤的实验研究[J].中国激光医学杂志,2011,20(3)：149-153,202-203.
[48]Ang KK, Berkey BA, Tu X, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma[J]. Cancer Res,2002,62(24):7350-7356.
[49]Chua DT, Nicholls JM, Sham JS, et al. Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy[J]. Int J Radiat Oncol Biol Phys,2004,59(1):11-20.
[50]Eriksen JG, Steriniche T, Askaa J, et al. The prognostic value of epidermal growth factor receptor is related to tumor differentiation and the over all treatment time of radio therapy in squamous cell carcinomas of the head and neck[J].Int J Radiat Oncol Biol Phys,2004,58(2):561-566.
[51]Bentzen SM, Atasoy BM, Daley FM, et al. Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as apredictive fact or for a benefit from accelerated radiation therapy in arandomized controlled trial[J].J Clin Oncol,2005,23(24):5437-5439.
[52]刘孟娟,周陈西,王增,等.83例西妥昔单抗联合放化疗不良反应分析[J].中国现代应用药学,2011,38(5)：485-488.
[53]王朴.生地黄的现代药理研究与临床应用[J].中国中医药现代远程教育.2008,6(8)：986.
[54]夏聪华,石森林,葛卫红,等.玄参药理活性研究进展[J].中国药师.2008,11(8)：911-912.
[55]张健萍,李连珍,赵洪江,等.牡丹皮的化学成分、药理作用及临床应用研究概况[J].中华中医药杂志.2006,21(5)：295-297.
[56]王林青.中药金银花提取物杭炎作用研究[J].中国畜牧兽医.2008,35(8)：82.
[57]戴幼艺,刘安保,戴新华.西乐葆对鼻咽癌CNE-1细胞增殖和凋亡的影响.中国现代医学杂志.20(7)：988-991.
[58]刘伟胜,徐凯,等.肿瘤科专病中医临床诊治[M].第2版,北京：人民卫生出版社,2005,1.
[59]田道法,何迎春.鼻咽癌前病“气虚染毒”病机理论研究[J].中医耳鼻喉科学研究杂志.2008,7(1)：24-29.
[60]Cho W C, Chen H Y. Clinical efficacy of traditional Chinese medicine as a concomitant therapy for nasopharyngeal carcinoma:a systematic review and meta-analysis[J]. Cancer Invest,2009,27(3):334-344.
[61]曹远东,孙新臣,成红艳,等.汉防己甲素配合放射线增敏治疗鼻咽癌的临床研究[J].东南大学学报(医学版),2008,27(2)：106-109.
[62]谢强,赵荡,刘兴京,等.复方苦参注射液联合适形调强放疗治疗鼻咽癌的临床研究[J].国际内科学杂志,2008,35(3)：133-135.
[63]陈绪元,朱宇熹,陈晓品,等.平消胶囊与放疗同步治疗中晚期鼻咽癌增敏研究[J].临床肿瘤学杂志,2005,10(02)：163-165.
[64]苏旭春,肖柳珍,刘城林,等.普济煎液配合放、化疗治疗EB病毒感染鼻咽癌30例临床观 察[J].中医药导报,2005,(01)：32-33+36.
[65]金红,吴湘玮.养阴解毒法减低鼻咽癌放射反应24例疗效观察[J].山东中医杂志,2005,24(1)：17-19.
[66]童克家,王存吉.口疳清热汤治疗鼻咽癌放疗口咽黏膜毒副反应33例[J].中医药导报,2011,17(5)：30-32.
[67]刘淑美.生脉饮加味治疗鼻咽癌放疗时涎腺受损的临床研究[J].中国医药导报,2010,7(16)：13-15.
[68]王旺胜.养阴清热口服液对鼻咽癌放疗所致唾液腺损伤影响的临床研究[J].时珍国医国药,2008,19(3)：729-730.
[69]Bao Y X, Wong C K, Leung S F, et al. Clinical studies ofimmunomodulatory activities of Yunzhi-Danshen in patients with nasopharyngeal carcinoma[J]. J Altern Complement Med,2006,12(8):771-776.
[70]袁国荣,卢丽琴,钦志泉,等.加味清营汤对鼻咽癌放疗增效减毒的临床研究[J].中医药学刊,2006,24(4)：670-671.
[71]许利纯,张红,曾柏荣.血栓通加归七软坚散外敷治疗鼻咽癌放疗后张口困难疗效观察[J].中国中医药信息杂志,2007,14(1)：60-60.
[72]彭桂原.痰热清注射液治疗鼻咽癌放疗所致放射性咽喉炎临床观察[J].中国中医急症,2008,17(6)：761-762
[73]赖振源,任益民,黄碧松.中西医癌症诊断与治疗汇编[M].第1版,中华民国中医癌症医学会、中华民国中医肝病医学会、台湾中医皮肤科1学会联合出版.中华民国98年,152-153.
[74]Xu JH, et al. Curcumin inducing apoptosis and inhibiting expression of P210bcr/ abl protein in human chronic myelogenous leukemia k562 cells[J]. FAS EB Journal, 2000,14(8):1516.
[75]Lin JK, Lin-shiau SY. Mechanisms of cancer chemoprevention by curcumin [J]. Proc Nat 1 Sci Counc ROC(B),2002,25(2):59-66.
[76]麦镇江.姜黄素的药理作用研究进展[J].中药材,2004,27(9)：698-701.
[77]曾山,姚运红.姜黄素与化疗药物联合抗癌作用的研究进展[J].实用癌症,2010,25(2)：218-220.
[78]Zheng LD, Tong QS, Wu CH. Inhibitory effects of curcumin on apoptosis of human ovary cancer cell line A2780 and its molecular mechanism[J]. Ai Zheng,2002,21(12):1296-1300.
[79]许刚,黄文.姜黄素防治肿瘤的机制研究进展[J].国外医学生理病理科学与临床分册,2003,23(2)：152-154.
[80]赵承光,杨菊,梁栋楼,等.新型含氟姜黄素类似物的合成、晶体结构及抗肿瘤活性[J].有机化学,2010,30(2)：289-294.
[81]刘强和,孔中雨,向秋,等EGCG对鼻咽癌细胞株CNE-1生长及其survivin表达的影响[J].山东医药.2009,49(10)：26-27.
[82]湛达河,胡建兵,达世俭,等.雷公藤红素对鼻咽癌CNE-1细胞增殖抑制和放射增敏作用的初步研究[J].癌症进展.2010,8(5)：491-499.
[83]刘姬艳,马润娣,于立坚,土贝母苷甲对人鼻咽癌上皮细胞丝裂原活化蛋白激酶活性的影响[J].北京中医,2007,26(2)：119-121.
[84]翁昔阳,马润娣,于立坚.土贝母营甲诱导人鼻咽癌细胞CNE-2Z凋亡[J].癌症,2003,22(8)：806-811.
[85]孙伟,肖家祁,王淳凯,等.精油对人鼻咽癌细胞生长抑制的研究[J].上海中医药杂志,2005,39(9)：53-55.
[86]顾生玖,杨娜,朱开梅.槲皮素抑制人鼻咽癌CNE2细胞生长并诱导其凋亡的研究[J].中国实验方剂学杂志,2011,17(13)：192-194.
[87]韦世秀,刘成军,李牡艳,等.眼镜蛇毒神经生长因子诱导人鼻咽癌CNE-2细胞凋亡作用的研究[J].中国医院药学杂志,2008,28(22)：1909-1912.
[88]唐艳,曹建平,樊赛军,等.青蒿素对人鼻咽癌CNE细胞的放射增敏作用及机制的研究中华放射医学与防护杂志[J].2010,30(3)：280-282
[89]向银洲,余林,魏莲枝,等.冬凌草甲素对鼻咽癌HNE-1细胞株生长及其PCNA、Caspase-3表达的影响[J].山东医药,2010,50(50)：20-22.
[90]陈增边.黄芪多糖的抑瘤作用及注射用黄芪多糖对鼻咽癌放射治疗患者免疫功能的影响[J].临床医学.2010,30(5)：23-24.
[91]韦世秀,刘成军,李牡艳,等.黄芪注射液诱导人鼻咽癌CNE-2细胞凋亡及对细胞周期阻滞的研究[J].广西医科大学学报,2007,(05)：704-705.
[92]梅全喜,刘朝晖.中药复方防治鼻咽癌的药理研究进展[J].中国民族民间医药,2010,22-24.
[93]胡彬雅,田道法,何迎春.益气解毒颗粒影响鼻咽癌细胞HNE1增殖活力的实验研究[J].临床耳鼻喉头颈外科杂志.2009,23(12)：558-560.
[94]邓国英,范晓磊,杨如虹,等.参杞合剂对人鼻咽癌细胞CNE细胞周期及凋亡的影响[J].中国微生态学杂志,2007,19(3)：246-248.
[95]范晓磊,邓国英,周慧敏.参杞合剂诱导鼻咽癌细胞凋亡及其作用机制探讨[J].中医杂志.2008,49(5)：356-358.
[96]刘宗潮,简少文,冯公侃,等.鼻咽清毒剂对EB病毒抗原表达抑制作用和细胞毒作用的研究[J].中草药,1999,30(增刊)：158-159.
[97]韩虹,盛晓丽,崔勇,等.鼻咽清毒颗粒对鼻咽癌的体内抑制作用[J].广东医学,2009,30(9)：1244-1245.
[98]刘宗潮,简少文,李华忠,等.抗EB病毒口服液对EB病毒转化力的抑制作用.肿瘤防治杂志,2004,11(8)：790-792.
[99]刘宗潮,简少文,李华忠,等.抗EB病毒口服液对EB病毒抗原表达的抑制作用及其细胞毒作用.中草药.2004,35(5)：542-545.
[100]林壮民,王爱平,梅清华,等.抗EB病毒口服液对Beagle犬的长期毒性研究.中国药房,2006,17(14)：1054-1056.
[101]林壮民,贾冬,兰树敏,等.抗EB病毒口服液对大鼠的长期毒性实验.中药材,2006,29(6)：583-585.
[102]梅全喜,钟希文,符立梧,等.不同中药组方对人鼻咽癌细胞CNE-2体外抑制作用的比较研究.中国药房.2009.20(15)：1130-1131.
[103]景艳,唐安洲.中药在鼻咽癌综合治疗中的研究进展[J].实用医学杂 志.2010,26(9)：1487-1489.
[104]高月娟,孟妍,张艳丽.太子参抗应激作用的实验研究[J].齐齐哈尔医学院学报,2011,32(12)：1886-1887.
[105]王朴.生地黄的现代药理研究与临床应用[J].中国中医药现代远程教育.2008,6(8)：986.
[106]朱良春.朱良春用药经验集[M].第2版.长沙：湖南科学技术出版社.2007.10：226-227.
[107]李元青,马成杰,陈信义,等.三七活性成分抗肿瘤作用及其免疫学机制初探[J].北京中医药大学学报(中医临床版),2008,15(1)：17-19.
[108]Kastelan Z,Lukac E,Derezic D,et al.Lymphocyte subsets, lymphocyte reactivity to mitogens, NK cell activity and neutrophil and monocyte phagocytic functions in patients with bladder carcinoma [J].Anticancer Res,2003,23(6):5185.
[109]Tsai JP,Chen HW,Cheng ML,et al.Analysis of host versus tumor interaction in cancer patients:opposing role of transforming growth factor-β1 and interleukin-6 in the development of in situ tumor immunity[J].Immunobiology,2005,210(9):661-671.
[110]吕贺,朴成国,李香丹,等.中药抗肿瘤机制的研究现状[J].医学综述,2011,17(19)：3004-3006.
[111]Van Sandick J W,Boermeester M A,Gisbertz S S,et al.Lymphocyte subsets and T(h)1/T(h)2 immune responses in patients with ade2 nocarcinoma of the esophagus or oesophagogastric junction relation t opTNM stage and clinical outcome[J].Cancer Immunol Imnmnother,2003,52(10):617.
[112]Hadden J w.Immunodeficiency and cancer:prospects for correction [J].Int immunopharmacology,2003,3 (8):1061.
[113]何耀溅.大计量化疗治疗恶性肿瘤[J].匡际医药卫生报,2004,10(20)：56。
[114]王晓燕,徐爱运.化疗药物的毒副反应及护理[J].中华现代护理学杂志,2005,2(11)：1206-1207.
[115]欧阳素贞,王双山,田素香等.淫羊藿一蜂胶合剂促进鸡细胞免疫的研究[J].畜牧兽医学报,2006,37(1)：80-83.
[116]席孝贤,贺新怀.中药相关成分对T细胞亚群的调节作用[J].陕西中医学院学报,2002,25(2)：51-533.
[117]胡宇莉,廖晓兵,黎建华等.穿心莲对肉鸡体液免疫的影响[J].中国兽药杂志,2004,40(9)：24-27.
[118]吴小丽,蔡云清,赵岩等.蒲公英提取物对小鼠免疫功能的调节作用[J].南京医科大学学报(自然科学版),2005,25(3)：163-165.
[119]储岳峰,颜新敏,胡元亮等.几种中药成分的免疫增强活性及其作用效果[J].中国兽医科技,2005,35(1)：67-70.
[120]李虹,马莉,等.鼻咽癌患者外周血T细胞亚群及活化T淋巴细胞的检测及放疗后对其变化的影响[J].微量元素与健康研究,2006,23(3)：10-12
[121]王朝阳,李桂生,等.局部晚期鼻咽癌患者放化疗及随访过程中T细胞亚群的变化规律[J].实用医学杂志,2008,24(15)：2581-2583.
[122]方征,李鸣,等.鼻咽癌患者外周血NK细胞及T细胞亚群的变化[J].湖南医学,2001,18(6)：412-414.
[123]聂明,唐安洲,黄光武,等.鼻咽癌患者放疗前后外周血EBV-DNA和细胞免疫水平的研究[J].肿瘤防治研究,2011,38(04)：380-383.
[124]应妩,王毓三.全国临床检验操作规程[M].第二版,南京：南京东南大学出版社,1997； 361
[125]毛明华,黄世超,余慧珠.肿瘤患者放、化疗后外周血淋巴细胞损伤和免疫功能改变的研究[J].肿瘤,2004,24(6)：589-591.
[126]梅全喜.鼻咽癌的中医治疗.北京：中国中医药出版社,2010：176.
[127]刘成军,韦世秀,李牡艳,等.黄芪注射液对人鼻咽癌CNE-2细胞株的抑制作用研究[J].中国药房,2005,16(18)：1376-1378.
[128]阿依恒·曲库尔汗,尼力帕尔·阿力木,亚力坤·亚生,等Genistein对人鼻咽癌细胞系CNE抑制增殖和促进凋亡的作用及机制探讨[J].临床耳鼻咽喉头颈外科杂志,2011,25(18)：843-847.
[129]蔡于琛,冼励坚.小檗碱体内外对人鼻咽癌细胞CNE-2生长的抑制作用[J].中草药,2006,37(10)：1521-1526.
[130]罗晓婷,熊亮,李思思,等.橙皮苷提取物对人鼻咽癌CNE-2Z细胞增殖和细胞周期的影响[J].时珍国医国药,2011,22(9)：2202-2204.
[131]Dunne AL, Price ME, Mothersill C,et al.Relationship between clonogenic radiosensitivity, radiation-induced apoptosis and DNA damage/repair in human colon cancer cells [J].Br J Cancer,2003,89(12):2277-2283.
[132]Melet A, Song K, Bucur O,et al.Apoptotic pathways in tumor progression and therapy [J].Adv Exp Med Biol,2008,615:47-79.